Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: New insights on congenital pulmonary airways malformations revealed by proteomic analyses

Fig. 1

Expression of SOX2 and SOX9 during fetal development, and in CPAM cysts and control lung. a. Immunohistochemical staining of human fetal lung tissue at 16 weeks of gestation (canalicular stage) with SOX2, SOX9 and ACTA2 antibodies. Note the differential expression of SOX2 and SOX9 at the tip of the buds. b. Immunostaining of CPAM 1, CPAM 2 and control lung with SOX2 and SOX9 antibodies. Note the strong staining of the bronchial epithelium and of the epithelial cyst lining c. Graph comparing SOX2 and SOX9 stained surface with the total measured surface in CPAM and in control tissue. Alveoli compared to all other samples: *** p < 0.001, ** p < 0.01. * p < 0.05. CPAM 1 compared to CPAM 2 ♦♦ p < 0.01, CPAM 2 compared to Bronchi p < 0.05. N = 3 different patients, each point corresponds to the mean of 10 random pictures per patient. Scale bars: 100 μm

Back to article page